SAB Biotherapeutics, Inc.
Monday, February 26, 2024
SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing fully-human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The company’s lead asset, SAB-142, targets Type-1 diabetes (T1D) with a disease-modifying therapeutic approach that aims at changing the treatment paradigm by delaying onset and potentially preventing disease progression. SAB-142: Type 1 Diabetes (T1D) - Fully human, broadly neutralizing immunoglobulin (hIgG) treatment being developed to delay the onset and progression of T1D with a mode of action similar to that of clinically validated rabbit-derived anti-thymocyte globulin (rATG or Thymoglobulin). First-in-class fully-human hIgG treatment aimed to provide superior safety for delaying onset and progression of clinical Stage 3 Type 1 Diabetes by eliminating risk of serum sickness and high immunogenicity.
CEO/Top Company Official
Eddie J. Sullivan, PhD Co-Founder, President & CEO
Lead Product in Development
SAB-142 for Type 1 Diabetes
Development Phase of Primary Product
Number Of Unlicensed Products
1. SAB-176 for Influenza. SAB recently received Fast Track Designation and Breakthrough Therapy Designation from the U.S. Food and Drug Administration for SAB-176, which targets multiple strains of influenza, based upon positive clinical data from a Phase 2a trial.